TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma
Tuesday, October 27, 2020
Knight Therapeutics Inc., a leading Pan American (ex. EU) specialty pharmaceutical company (“Knight”), announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. (“Gilead”) ) for the marketing of AmBisome® (liposomal amphotericin B) in Brazil. The agreement will enter into force as of 1 st January 2021.
“We are pleased to continue this already established partnership and are very grateful to Gilead for the continued trust in the Knight team,” said Samira Sakhia, President and COO of Knight. Our Brazilian team launched AmBisome in Brazil over 20 years ago and we are excited to continue the great work we have done with patients and physicians ”.
"The signing of this new agreement extends the historic collaboration between Gilead and Grupo Biotoscana (" GBT ") and confirms Knight's assessment of the GBT acquisition," said Amal Khouri, vice president of business development at Knight.
“Gilead values the ongoing partnership with GBT to meet medical needs in Brazil,” said Ahmed Afifi, vice president and head of the Latin America region at Gilead Sciences. With this new agreement, we are pleased to continue our cooperation with the extended GBT / Knight team to enable Brazilian patients to benefit from AmBisome ”.
About AmBisome ®
AmBisome® (Liposomal Amphotericin B) is a sterile lyophilized, non-pyrogenic intravenous infusion of liposomal amphotericin B. This medicinal product is indicated (1) for the treatment of serious deep mycotic infections and / or endemic and opportunistic systemic mycoses, (2) for the treatment of fever of undetermined origin (FOI) in neutropenic patients for whom the FOI corresponds persistent fever, which does not respond to antibiotic therapy after 96 hours and which is very indicative of a systemic fungal infection, (3) as the primary therapy for visceral leishmaniasis in immunocompetent patients. AmBisome® is a registered trademark of Gilead Sciences, Inc. and is the subject of a license from Gilead and has been in the portfolio of Knight's Brazilian subsidiary for over twenty years. Knight's subsidiaries are responsible for the distribution and commercial activities of AmBisome® in Brazil as well as Bolivia, Paraguay and Peru.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., based in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or licensing distribution rights for innovative pharmaceutical products for the Canadian and Latin American markets. . Knight has a controlling interest in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company. Knight's shares trade on the TSX under the symbol "GUD". For more information about Knight Therapeutics Inc., visit its website at www.gud-knight.com or www.sedar.com .
Forward-looking statements
This document may contain forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. Knight Therapeutics Inc. considers that the assumptions on which these forward-looking statements are based are believed to be reasonable at the date they are made, but cautions the reader that these assumptions about future events, many of which are beyond the control of Knight Therapeutics inc. and its subsidiaries, may prove to be incorrect. Factors and risks that could cause actual results to differ materially from expected results are discussed. a discussion in the annual report and in the latest annual information form of Knight Therapeutics inc. for the year ended December 31, 2019 filed on www.sedar.com . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statement, whether in response to new information or to future events, except as required by law.
CONTACTS
Investor information
Knight Therapeutics Inc.
Samira Sakhia
President and Chief Operating Officer
Phone. : 514-678-8930
Fax : 514-481-4116
Email: info@knighttx.com
Website: www.gud-knight.com
Arvind Utchanah
Chief Financial Officer
Phone. : 514-484-4483 ext. 115
Fax : 514-481-4116
Email: info @ knightt x .com
Website: www.gud-knight.com
